Latest News and Press Releases

PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.

Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine monthsSusvimo’s innovative technology via the Port...

PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...

CALGARY, Alberta, May 15, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) is pleased to announce the results of the election of board members at its 2025 Annual...

VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at...

Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Water Quality Testing Equipment Market Opportunities and Strategies to 2034" has been added to ResearchAndMarkets.com's offering. The global water...

PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...

PDSB announced that Infectimune® immune response data were featured at the American Association of Immunologists’ IMMUNOLOGY2025™ Annual Meeting.

First Quarter Revenue was $559.2 million, a 14.0% increase over the prior year period Gross margin increased 25.9% to $183.6 million compared to Q1 2024 First Quarter Net income was $5.2 million...